Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

DxS launches B-RAF mutation detection kit

DxS : 18 October, 2007  (New Product)
DxS has added a B-RAF Mutation Detection Kit to its range of oncogene mutation products.
DxS is a molecular diagnostic company specialising in products to detect mutations in tumours. Understanding cancer mutation status can help select the optimal drug therapy for a patient.

The DxS B-RAF Assay detects V600E, the most common mutation in the B-RAF oncogene, which occurs in many types of cancer including melanoma, colorectal and lung. Tumours with the V600E mutation are exquisitely sensitive to drugs that inhibit the MEK pathway; therefore this Assay is likely to be useful to investigate which patients will respond to these drugs. Companies with MEK inhibitor drugs in development include Pfizer, AstraZeneca and Roche.

The kit is highly selective and robust, detecting the mutation in a background of wild type genomic DNA in a real time PCR Assay based on DxS Scorpions technology. The Assay can detect less than one percent of mutant in a background of wild type genomic DNA and has a limit of detection of five copies or below. The un-paralleled selectivity of the technology means that the kit detects mutations frequently missed by sequencing methods.

Commenting on the B-RAF test, Dr Stephen Little, DxS CEO said, 'Patient mutation status is becoming a vital predictor of response to some targeted cancer therapeutics. The DxS Scorpions test format is rapidly gaining acceptance as both the best and easiest method of mutation testing and this latest addition to our product range will help in the development of personalised medicine for cancer.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo